Efficient Difluoromethylation of Alcohols Using TMSCF<sub>2</sub>Br as a Unique and Practical Difluorocarbene Reagent under Mild Conditions
作者:Qiqiang Xie、Chuanfa Ni、Rongyi Zhang、Lingchun Li、Jian Rong、Jinbo Hu
DOI:10.1002/anie.201611823
日期:2017.3.13
difluoromethylation of alcohols using commercially available TMSCF2Br (TMS=trimethylsilyl) as a unique and practical difluorocarbene source is developed. This method allows primary, secondary, and even tertiary alkyl difluoromethyl ethers to be synthesized under weakly basic or acidic conditions. The reaction mainly proceeds through the direct interaction between a neutral alcohol and difluorocarbene
[EN] HPK1 INHIBITORS, PREPARATION METHOD AND APPLICATION THEREOF<br/>[FR] INHIBITEURS D'HPK1, PROCÉDÉ DE PRÉPARATION ET UTILISATION ASSOCIÉS
申请人:ZHUHAI YUFAN BIOTECHNOLOGIES CO LTD
公开号:WO2019206049A1
公开(公告)日:2019-10-31
Disclosed are HPK-1 inhibitors having a structure represented by Formula (X), pharmaceutical compositions comprising the HPK-1 inhibitors, methods of using the HPK-1 inhibitors, such as treating cancers, methods of preparing the HPK-1 inhibitors, and the synthetic intermediates.
Difluorocarbene‐Induced Ring‐Opening Difluoromethylation‐Halogenation of Cyclic (Thio)Ethers with TMSCF
<sub>2</sub>
X (X=Br, Cl)**
作者:Rongyi Zhang、Qigang Li、Qiqiang Xie、Chuanfa Ni、Jinbo Hu
DOI:10.1002/chem.202103428
日期:2021.12.20
protonation of difluromethylene oxonium or sulfonium ylides (generated from diflurorocarbene and cyclic (thio)ethers) constitutes the formal activation of C−O/S bond of (thio)ethers with difluormethyl cation, thus facilitating the ring-opening difluoromethylation-halogenation of cyclic (thio)ethers. (TMS=trimethylsilyl).
[EN] BICYCLIC COMPOUNDS FOR USE AS RIP1 KINASE INHIBITORS<br/>[FR] COMPOSÉS BICYCLIQUES DESTINÉS À ÊTRE UTILISÉS EN TANT QU'INHIBITEURS DE LA KINASE RIP1
申请人:HOFFMANN LA ROCHE
公开号:WO2019072942A1
公开(公告)日:2019-04-18
The invention provides novel compounds having the general formula (I) or pharmaceutically acceptable salts thereof, wherein RA, RB1, RB2, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds as RIP1 kinase inhibitors.